Shape Therapeutics CEO Francois Vigneault has departed the RNA gene therapy startup, and chief scientific officer David Huss is filling the post while the Seattle …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Top of the morning to you, and a fine one it is. Clear blue skies and cool breezes are currently enveloping the placid Pharmalot campus,
Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3
Partial resistance to artemisinin, the recommended treatment for Plasmodium falciparum malaria, occurred in Ugandan children with severe disease who were treated with the drug, and